

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Balancing donor and recipient risk factors in liver transplantation: the value of D-MELD with particular reference to HCV recipients.

This is a pre print version of the following article:

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/89417> since 2016-10-18T23:01:57Z

Published version:

DOI:10.1111/j.1600-6143.2011.03732.x.

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

Title page

Title:

Balancing donor and recipient risk factors in liver transplantation. *The value of D-MELD with particular reference to HCV recipients in Italy.*

Authors:

AW Avolio, U Cillo, M Salizzoni, L De Carlis, M Colledan, G E Gerunda, V Mazzaferro, M Rossi, G Tisone, L Lupo, R Romagnoli, A Vitale, A Cucchetti, S Gruttadauria, L Caccamo, N Nicolotti, P Burra, S Agnes on behalf of the **Donor-to-Recipient Italian Liver Transplant (D2R-ILTx) Study Group**.

ABSTRACT

Donor-recipient match is a matter of debate in liver transplantation. D-MELD (donor age x recipient biochemical MELD) and other factors were analyzed on a national Italian database recording 5946 liver transplants. Primary endpoint was to determine factors predictive of 3-year patient survival. D-MELD cutoff predictive of 5 year patient survival <50% (5rPS<50%) was investigated. A prognosis calculator was implemented (www.D-MELD.com).

Differences among D-MELD deciles allowed their regrouping into three D-MELD classes (A <338, B 338-1628, C >1628). At 3 years, the odds ratio (OR) for death was 2.03 (95% confidence interval, [CI], 1.44-2.85) in D-MELD class C versus B. The OR was 0.40 (95%CI 0.24-0.66) in class A versus B. Other predictors were HCV (OR=1.42; 95%CI 1.11-1.81), HBV (OR=0.69; 95%CI 0.51-0.93), re-transplant (OR=1.82; 95%CI 1.16-2.87) and low-volume Center (OR=1.48; 95%CI 1.11-1.99). Cox regressions up to 90 months confirmed results. The hazard ratio (HR) was 1.97 (95%CI 1.59-2.43) for D-MELD class C versus B and 0.42 (95%CI 0.29-0.60) for D-MELD class A versus B. Recipient age, HCV, HBV, re-transplant were also significant. The 5yrPS<50% cutoff was identified only in HCV patients (D-MELD \geq 1750). The innovative approach offered by D-MELD and covariates is helpful in predicting outcome after liver transplantation, especially in HCV recipients.

Corresponding authors: Alfonso W Avolio, alfonso.avolio@tin.it; Umberto Cillo, cillo@unipd.it

INTRODUCTION

Donor-recipient match is a matter of debate in liver transplantation.⁽¹⁻³⁾ The combination of donor-related and recipient-related risk factors may offer a new therapeutic strategy with important effects on survival. The variability in donor organ quality and in recipient liver disease severity explains the various types of match adopted.^(4,5) Although the match or mis-match is sometimes purely the result of chance, in most cases surgeons and hepatologists can take the opportunity to combine organ and recipient on the basis of specific risk assessment methods, and/or to respect general principles (sickest first, maximization of resources, utility).

Optimization of donor-recipient match is the ultimate goal for improving liver transplant results. Its importance was reported in a small clinical series in 2005⁽²⁾, and confirmed one year later in larger series.^(3,5) Models able to predict 3-month and 12-month mortality from donor and recipient parameters have been developed on the European ELTR database (1988-2003).⁽⁶⁾ However, the hypothesis that donor-recipient match may have an even greater intrinsic prognostic role than that of donor organ quality or severity of the recipient disease, has recently been supported by the introduction of the D-MELD formula.⁽⁷⁾ D-MELD, the arithmetical product of donor age and Model for End-stage Liver Disease (MELD) score⁽⁷⁾, was developed on the American UNOS-STAR database (2003-2006) to combine donor-related and recipient-related risks; it has not yet been investigated in Europe.

In Italy donor and recipient characteristics show several peculiarities. Donor age is higher than in the United States^(3,7,9,10) or elsewhere in Europe.^(6,11,12) Unlike in major north American studies,^(1,6,9,13,14) we used donor age instead of the Donor Risk Index (DRI)⁽¹⁰⁾ to represent donor quality, because DRI is not applicable to the Italian donor population owing to the Caucasian ethnicity, absence of donation after cardiac death (DCD), higher prevalence of stroke death, limited sharing area and better outcome of split grafts.⁽¹⁵⁾ Finally, in Italy HCC patients undergoing liver

1
2
3 transplantation commonly show a lower degree of liver function decompensation as compared with
4
5 HCV candidates.⁽¹⁶⁾
6

7
8 Primary endpoint of the present study was to derive prognostic models according to donor-
9
10 recipient match in relation to 3-year patient survival, median follow-up being 36 months. Secondary
11
12 endpoints were to derive prognostic models of: a) patient survival at 90 days and 1 year; b) graft
13
14 survival at 90 days, 1 and 3 years; c) overall patient and graft survivals. As additional research D-
15
16 MELD was investigated in terms of possible *survival cutoffs*, according to the principle that
17
18 transplants with 5-year patient survival <50% (5yrPS<50%) should not be performed, so as to avoid
19
20 organ wasting⁽¹⁷⁾.
21
22
23
24
25
26
27

28 **PATIENTS and METHODS**

29 **Study population**

30
31
32 A database was filled with records of liver transplants performed in Italy from July 1st 2002 to
33
34 December 31st 2009, merging data prospectively collected by 21 Centers for clinical purposes and
35
36 outcome analyses. All donors were heart beating white Caucasians. Very few grafts (N=6, 0.1%)
37
38 were harvested abroad. Of the initial 5946 consecutive records, 5265 were included in the study after
39
40 the exclusion of pediatric cases, split, living donor and multiorgan transplants (Figure 1). Organ
41
42 allocation and donor-recipient match of second and third transplants were not analyzed but the *re-*
43
44 *transplant* status was included as an independent factor for the outcome of the first match.
45
46
47
48
49

50
51 Among the variables stored in each Center database, the following were selected on the basis
52
53 of evidence from previous major studies evaluating donor and recipient prognostic factors: donor age,
54
55 gender, Hepatitis B anti-core (HBcAb) status, recipient age, gender, etiology of liver disease,
56
57 concomitant etiologies, previous abdominal surgery, pre-transplant patency of portal vein, renal failure
58
59
60

1
2
3 (at least 1 dialysis during the week before transplantation), biochemical MELD score at transplant,
4
5 cold ischemia time (CIT), dates of listing, transplant, re-transplant, death, last follow-up, reason for
6
7 failure, and cause of death. Calculated data were D-MELD, donor-recipient gender match, donor-
8
9 recipient gender concordance, listing months, patient survival, graft survival.
10

11
12 The outcome was expressed as patient and graft survival. Follow-up ranged from 7 to 90
13
14 months (median, 36.5 months). Because donor age, MELD score at transplant and match policies
15
16 were subject to change over time, the study period was subdivided into different biennia (2002-2003,
17
18 2004-2005, 2006-2007, 2008-2009). Centers were classified in terciles as low volume (<100
19
20 transplants per biennium, N=11); medium volume (100-149 transplants, N=6); high volume (\geq 150
21
22 transplants, N=4). The biennium and the Center volume were included in models as dummy variables.
23
24 Donor-recipient match modalities were not codified by rules. Organ allocation was MELD-oriented.
25
26 Strictly for allocation purposes, stage-2 HCC patients were recoded as MELD 22 unless their
27
28 biochemical MELD was higher. Since the study aimed to evaluate the effect on prognosis of impaired
29
30 liver function and of its systemic effects, the biochemical MELD was utilized for the D-MELD
31
32 calculation, without adding any further points. The HCC status was evaluated as a dichotomic
33
34 variable.
35
36
37
38
39
40
41
42

43 **Statistical analysis**

44
45 Validity and completeness of data were first verified by data managers at transplant Centers. A
46
47 subsequent audit process was performed at the coordinating Center. All records were checked
48
49 (progressive number, ranges, consistency control for dates and multiple choice classification for death
50
51 causes and failure reasons)⁽¹⁹⁾ and pending cases were solved by data managers. Donor age, MELD,
52
53 recipient etiology, time of transplant and Center name are required fields in the patient listing process,
54
55 and utilized for organ allocation. All records were then considered correctly filled. In accordance with
56
57
58
59
60

1
2
3 the guidelines for the identification and validation of prognostic models in liver transplantation, only
4
5 parameters with at least 80% of data available were included in the analyses. Definitions were those
6
7 routinely used in the national listing process. No interpolation to manage missing data was performed.
8
9 An exploratory analysis in the whole study population was performed, plotting patient death against
10
11 donor age, MELD and D-MELD to generate cumulative logistic probability plots, as proposed by
12
13 Halldorson et al.⁽⁷⁾
14
15

16
17 According to Thuluvath et al.⁽²⁰⁾ and in conformity with statistical guidelines in organ
18
19 transplantation,^(21,22) the overall dataset was randomly split into a training set (2/3 of the records),
20
21 utilized to generate the main model, and a validation set (1/3). D-MELD was first investigated as a
22
23 continuous variable able to predict outcome, then a D-MELD categorical model was developed. For
24
25 this purpose, donor age, MELD and D-MELD were stratified into 10 decile groups.⁽²³⁾ To distinguish
26
27 between low-extreme, intermediate and high-extreme D-MELD cases, Mantel-Cox and Breslow tests
28
29 were applied to Kaplan-Meier analyses to assess the differences between deciles. Three D-MELD
30
31 classes were identified in the training set and the derived cutoffs were confirmed in the validation set.
32
33 Regrouping was therefore done, reclassifying D-MELD decile 1 as class A (D-MELD<338), D-
34
35 MELD deciles 2-9 as class B (D-MELD 338-1628), and D-MELD decile 10 as class C (D-MELD
36
37 >1628). D-MELD class B was used as reference for subsequent regression analyses.
38
39
40
41
42

43 Potential prognostic factors were studied in both sets by univariate analysis. Chi square and
44
45 Mann-Whitney tests were used to study significant factors for survival at fixed times. Mantel-Cox test
46
47 was used for survival curves. The prediction of mortality and failure was subsequently verified by
48
49 binary logistics using fixed times, and by Cox regression statistics using the overall follow-up. All
50
51 variables with a p-value <0.25 at univariate analyses entered the models. The results were expressed
52
53 as Odds Ratios (OR) and Hazard Ratios (HR) with 95% confidence intervals (95%CI). Statistical
54
55 evaluation of the model was also performed in order to avoid variable co-linearity. Adequacy of fit for
56
57
58
59
60

1
2
3 both sets was investigated using C-statistics and Hosmer-Lemeshow tests.⁽²⁴⁾
4

5 According to the hypothesis that the discrimination power of D-MELD class C should apply
6
7 even at high and extremely high values of donor age or MELD, all cases were split at the high (upper
8
9 quartile) and extremely high (upper decile) values of both donor age and MELD. Kaplan-Meier sub-
10
11 analyses were then performed according to the D-MELD 1628 limit.
12
13

14 The significance level was set at $p=0.05$. Statistical analyses were performed with JMP ver. 9.0
15
16 and SPSS ver. 18.0.
17
18

19 A website was implemented with a prognosis calculator on the basis of D-MELD and
20
21 covariates values (www.D-MELD.com, *password*: "D-MELD123").
22
23
24
25
26
27

28 **RESULTS**

29 **Preliminary logistic probability analysis**

30
31
32
33
34
35
36 Logistic probability plots confirmed the association of donor age, MELD, D-MELD with a
37
38 progressively decreasing probability of survival. The strongest prognostic power was obtained by D-
39
40 MELD (steeper curve, Figure 2).
41
42
43
44

45 **Stratification in deciles and in classes**

46
47 Overall median values for donor age, biochemical MELD, D-MELD were 57 (min 12, max
48
49 97), 15 (6-40) and 790 (66-3240), respectively. Donor age increased through the study period, leading
50
51 to a parallel increase in D-MELD until the 2006-2007 biennium (Figure S1).
52
53
54

55 Stratification of cases was performed according to D-MELD deciles and classes in terms of
56
57 patient (Figure 3A-B) and graft survival (Figure 3C-D). Significant differences were found solely
58
59
60

1
2
3 between decile 1 versus deciles 2 to 10 and between deciles 1 to 9 versus decile 10 (Table S1). Patient
4 characteristics in the three D-MELD classes are summarized in Table 1.

5
6
7 D-MELD stratified outcome better than either donor age or MELD alone (Figure 3 and Table
8 S2). The prevalence of the two extreme match-modalities varied according to the Center volume
9 (Figure 4). At higher volume Centers there was a shift towards a lower prevalence of low D-MELD
10 and higher prevalence of high D-MELD classes. The effect was even stronger in non-HCC recipients.
11
12
13
14
15
16
17

18 19 **Primary endpoint and related prognostic factors**

20
21 Significant factors identified at univariate analyses (data not shown) were included in the
22 logistic models to address the primary endpoint. At 3 years, the strongest predictor of death in terms of
23 OR was D-MELD. Cases in D-MELD class C had an OR equal to 2.03 (95%CI 1.44-2.85) as
24 compared to class B cases (Table 2). Conversely, cases in D-MELD class A had an OR equal to 0.40
25 (95%CI 0.24-0.66). Other significant predictive factors for death were HCV status (OR=1.42; 95%CI
26 1.11-1.81), and low-volume transplant Center (OR=1.48; 95%CI 1.11-1.99). Recipient age and re-
27 transplant status resulted predictive in the training set only (OR=1.015; 95%CI 1.002-1.028 and
28 OR=1.82; 95%CI 1.16-2.87, respectively). HBV status was predictive of a favorable outcome
29 (OR=0.69; 95%CI 0.51-0.93) in the training set only. The continuous D-MELD model is reported in
30 detail at the bottom of table 2.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 **Secondary endpoints and additional analyses**

49
50 In terms of *risk of death* at 90 days, the OR was 2.65 (95%CI 1.81-3.89) in D-MELD class C
51 versus class B (Table 2) and reached 2.32 (95%CI 1.68-3.21) at 1 year. Conversely, the OR at 90 days
52 was 0.46 (95%CI 0.24-0.86) in D-MELD class A and reached 0.43 (95%CI 0.26-0.72) at 1 year.
53
54
55
56

57 In terms of *risk of failure* at 90 days, the OR was 2.16 (95%CI 1.54-3.03) in D-MELD class C
58
59
60

1
2
3 versus class B (Table 2) and reached 2.05 (95%CI 1.52-2.77) at 1 year and 1.92 (95%CI 1.39-2.67) at
4
5 3 years. At 90 days, the OR was 0.41 (95%CI 0.24-0.72) in D-MELD class A; OR was 0.41 (95%CI
6
7 0.26-0.66) at 1 year and 0.42 (95%CI 0.27-0.67) at 3 years.

8
9
10 Cox regression models (Tables 2 and 3) confirmed the predictivity, in terms of overall
11
12 mortality and failure, of D-MELD, HCV status, HBV status and re-transplant status in both sets (Table
13
14 3). Recipient age resulted significant in both sets in terms of mortality but only in the validation set in
15
16 terms of failure. A low-volume Center was predictive of mortality in the training set only. See Table 3
17
18 for the continuous D-MELD model.

19
20
21 Hosmer-Lemeshow and C-statistics confirmed the adequacy of the logistics and Cox models in
22
23 both sets (Tables 2-3, Table S4).

24 25 26 27 28 **Stratification according to specific high-risk classes**

29
30
31 At Kaplan-Meier survival analyses, stratification according to high (≥ 68 , upper quartile) and
32
33 extremely-high (≥ 75 , upper decile) donor age and to high (≥ 21 , upper quartile) and extremely-high
34
35 (≥ 28 , upper decile) MELD showed that D-MELD class C values (> 1628 , 10th decile) were predictive
36
37 of poorer survival both in the overall population and in the high and extremely-high risk cases.
38
39 Focusing on high and extremely-high cases for both donor age and MELD, D-MELD class C had
40
41 worse survival than intermediate plus low-risk classes (B plus A, Figure S2).

42
43
44
45 To explore potential clinical applications of D-MELD we searched for specific patients
46
47 subgroups with a 5yrPS $<50\%$ predictable by D-MELD. The cutoff value predicting the 5yrPS $<50\%$
48
49 was identified in HCV patients only (D-MELD ≥ 1750 , Figure 5). The identification of a D-MELD
50
51 cutoff in any other situation was precluded by the smaller number of cases with other etiologies and
52
53 conditions, together with their better outcome.
54
55
56
57
58
59
60

DISCUSSION

Our study was performed on a national basis over an 8-year period. The wide spectrum of donor age and MELD makes the study population an ideal “match laboratory” because the variability in both donor quality and recipient disease severity facilitated the development of algorithms able to stratify the risk. We primarily evaluated D-MELD as a continuous variable according to Halldorson et al.⁽⁷⁾ and then stratified data in D-MELD deciles, obtaining a graphic representation of outcome in terms of graft and patient survival. The categorical approach, stratifying survival in deciles, was almost progressive, spanning a broader interval than previously reported.^(6,7,10,25) D-MELD predicted the outcome through the whole database and it maintained its prognostic power throughout the follow-up, with an intrinsically good performance at high and extremely-high values of donor age and MELD. In addition, although the arithmetical nature of D-MELD strengthens the weight of donor age and MELD particularly when both values are high, D-MELD remained predictive even at low values. According to the D-MELD approach, candidates previously judged as risky because of an extremely-high MELD showed a down-leveling of the risk when matched to a young donor (e.g. MELD=40, donor age=20->D-MELD=800) and likewise elderly grafts previously judged as risky because of an extremely-high donor age showed a down-leveling of the risk when a graft characterized by an extremely-high donor age was matched to a low-MELD candidate (e.g., donor age=80, MELD=10->D-MELD=800). On this basis, the prospective, intentional adoption of the D-MELD approach could prove beneficial in balancing donor and recipient risk factors. Further evidence to support this concept is derived from DCD studies showing an enhanced survival effect of donor quality.^(32,33) Patients with a low biochemical MELD could better sustain a complicated postoperative course after grafting with a high-risk organ but, from a justice perspective, we must ask ourselves whether and why it is fair to expect them to bear the extra risk of a complicated postoperative course.

Using logistic and Cox regression statistics, we identified additional independent determinants

1
2
3 of outcome according to different time endpoints: recipient age, HCV, HBV, pre-transplant portal
4 thrombosis, re-transplant, biennium of transplantation and Center volume. As recently reported,⁽²⁶⁾
5 portal thrombosis resulted significant on 90-day and 1-year graft survival only and the effect of
6 recipient age was significant on 1-year patient survival only. The outcome was impaired in cases of a
7 high D-MELD combined with an old recipient, and even more so in an old recipient with portal
8 thrombosis. As shown by other Authors, HCV typically entails an additional risk, while HBV has a
9 protective effect, and the effect of the primary disease is generally more evident in the long
10 run.^(11,13,27,28) However, the prognostic power of HCV, portal thrombosis and recipient age was less
11 strong than that of D-MELD even if their role was relevant in cases with a D-MELD value close to the
12 identified limit of 1628. We failed to demonstrate a prognostic effect of pre-transplant abdominal
13 surgery, gender match, gender concordance, CIT, and HBcAb-positivity, although these factors were
14 found significant by other Authors.^(6,9,13,19,29-31) Due to the peculiar donor characteristics, extreme
15 attention was paid to keeping the CIT as short as possible. Moreover, the improvement in the D-
16 MELD model we obtained with the introduction of other significant covariates did not reduce the
17 power of D-MELD itself, whose major strength lies in its immediacy of calculation.

18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38 The high prevalence of HCC represents a peculiarity of our study population. Nevertheless,
39 HCC was not recognized as an independent determinant of outcome. This is probably due to the fact
40 that the majority of patients complied with Milan criteria, a condition that keeps down the risk of
41 recurrence.^(16,34) Due to the common combination between cirrhosis and HCC, in our database we
42 cannot differentiate patients *listed for HCC* from those *listed with HCC*. In D-MELD class B, which
43 accounts for 80% of cases, donor age and MELD were matched at different levels of risk, while in D-
44 MELD class A and in D-MELD class C, donor age and MELD were matched at the corresponding
45 level (young-donor to low-MELD and old-donor to high-MELD, respectively). This explains the low
46 number of HCC patients in D-MELD class C, in which all patients, including those with HCC, were
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 transplanted for decompensated cirrhosis.

4
5 Although our study design set the primary endpoint at 3 years, the peculiarity of the HCV
6
7 population allowed Kaplan-Meier sub-analyses to be performed in order to identify the 5yrPS<50%
8
9 cutoff. The concept of the 5yrPS<50% threshold was introduced in 1999 to avoid organ
10
11 wasting^(17,35,36). A similar metric was also utilized when exploring an extension of Milan criteria for
12
13 HCC.⁽³⁸⁾ However, in both approaches, the 50% value and its 5 year time-limit were arbitrarily set. As
14
15 yet, stratification in relation to the 5yrPS<50% cutoff has not been done using a single quantitative
16
17 parameter.^(38,39) Nor have different percentages and time-limits been identified according to etiology.
18
19 In the present study HCV and HBV had a predictive role in several prognostic models. Since HBV
20
21 patients had a more favorable outcome, the 5yrPS<50% cutoff could not be identified among them.
22
23 Instead, we identified 7% of HCV patients (3% of all transplants) exceeding the cutoff. This is
24
25 probably due to the fact that a strong contributing factor to the worse prognosis of HCV recipients is
26
27 the negative effect of donor age, as repeatedly reported.^(11,28) In summary, while the D-MELD 1628
28
29 limit predicted poor prognosis in the overall dataset, an even poorer prognosis was predicted by the
30
31 5yrPS<50% cutoff (D-MELD \geq 1750) in HCV patients.
32
33
34
35
36
37

38 Using the 5yrPS<50% cutoff could be misleading since it is not evidence-based. However, it
39
40 identifies a sub-group of HCV patients with a performance status below the currently defined minimal
41
42 survival requirements. The 5yrPS equal to 50%, indeed, should be read as the minimal sustainable
43
44 survival rate considering the competition within the waiting list for the same given graft: this is a
45
46 potential operative limit depending on the characteristics of both donor and listing populations. It is
47
48 well fitted to the Italian population in which organ shortage is critical. Organ availability is inevitably
49
50 a key point. Assuming the same high D-MELD value, an organ from an elderly donor is likely to fail
51
52 in an HCV but not in an HBV recipient. This depicts the shift from the 5yrPS<50% *transplant cutoff*
53
54 towards a novel concept: the “*unsustainable match cutoff*”. We should note that the recent
55
56
57
58
59
60

1
2
3 introduction of the survival benefit approach is radically changing the modality of result reporting
4
5 after liver transplantation. After stratification for MELD, this model was designed to quantify the
6
7 survival gain between undergoing transplantation and staying on medical care.⁽⁴⁰⁾ The model denies a
8
9 transplant to patients with a low biochemical MELD and absence of HCC nodules. We believe that the
10
11 approach we suggest does not conflict with the clinical application of 2nd generation survival benefit
12
13 models, that are eagerly awaited. They include MELD components, *survival with* and *without*
14
15 *transplant*, donor age, recipient age, primary disease and other determinants of outcome.^(41,42,43) This
16
17 type of modeling could better link prognosis to resource availability and be strictly tailored to different
18
19 populations according to their donor and recipient characteristics. Hopefully, the next survival benefit
20
21 studies will offer final answers to the problem of match in patients with low biochemical MELD.
22
23
24

25
26 While the effect of the biennium during the 8-year study period was not relevant there was, as
27
28 expected,^(6,44,45) a predictive effect of low volume Center on 3-year mortality at logistic regressions.
29
30 Interestingly, in terms of graft failure, the difference was not significant. It could be hypothesized that
31
32 access to elective re-transplantation might be limited in some low-volume Centers. However, we
33
34 should note that the larger the Center volume, the higher the prevalence of high D-MELD classes.
35
36 This finding, that is more evident in non-HCC patients, implies that, in general, high and medium
37
38 volume Centers do a bit better with high-risk match combinations.
39
40
41
42

43
44 There were three main reasons why we developed the prognosis calculator. Firstly, to provide
45
46 a direct example of how donor and recipient factors interact in determining prognosis. Secondly, to
47
48 help hepatologists, transplant surgeons and transplant coordinators in the everyday practice of
49
50 matching donor and recipient factors when choosing the recipient. Lastly, to allow researchers from
51
52 other countries to perform an external validation.
53
54

55
56 Some differences with respect to the American D-MELD study⁽⁷⁾ need to be highlighted.
57
58 Firstly, the methodology adopted in our study (a larger number of factors evaluated, time-based
59
60

1
2
3 endpoints, training set and validation set, decile method, logistic regressions) is coherent with the
4
5 guidelines for statistical analysis in organ transplantation.^(21,22) Secondly, the data collection period,
6
7 minimum and median follow-up are nearly twice as long. Nevertheless, our cutoff exceeds the
8
9 American one by only 28 units, quite a small difference considering the older donor age and the higher
10
11 prevalence of HCV in the study population. Moreover, our model identifies three match combinations
12
13 with a potential clinical applicability. The 1628 limit has an obvious implication in capping the risk of
14
15 death⁽⁷⁾, and the 338 limit identifies a pool of organs which could theoretically be reserved for the
16
17 sickest patients. Finally, the identification of other predictive factors and the definition of the
18
19 5yrPS<50% cutoff in HCV recipients enrich our model.
20
21
22

23
24 Our study suffers from several limitations. Although based on prospectively filled Center-
25
26 specific databases, our analysis remains retrospective like all other large prognostic studies. Secondly,
27
28 the high number of patients harboring HCC may represent a selection bias. That means that
29
30 coefficients, analyses and conclusions obtained in this Italian study may not be directly applicable to
31
32 countries with different donor and recipient populations. Thirdly, the intentional use of the D-MELD
33
34 approach will narrow the donor pool for the sickest candidates who are in the greatest need of
35
36 transplantation, while widening the donor pool for less ill candidates. We are aware that because few
37
38 patients exceeded the D-MELD 1628 limit, and even fewer HCV patients exceeded the 5yrPS<50%
39
40 cutoff, a meaningful evaluation of the accuracy of this approach could be performed only on huge
41
42 continental databases. We are also in need of more complex models in HCV patients transplanted with
43
44 HCC and in those transplanted for HCC, in whom neither the severity of liver disease nor its prognosis
45
46 are correctly quantified by MELD. In this setting the outcome could be more strictly related to other
47
48 factors (stage, time on list, bridging procedure, surgical or medical treatment of recurrences).
49
50
51
52
53

54
55 In conclusion, D-MELD, a simple numerical expression of the donor-recipient match, remains
56
57 the main determinant of graft and patient survival after liver transplantation. The use of D-MELD and
58
59
60

covariates can support the intentional balancing of risk factors, limiting high risk donor-recipient matches especially when the primary disease is HCV cirrhosis.

ACKNOWLEDGEMENTS

Funding: the study was supported by Lazio Transplant Agency (LTA), Rome, Italy and by Liver Transplant Center, Catholic University, Rome, Italy. The LTA had no role in study design, data collection, data analysis, data interpretation, or writing the paper. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. The authors would like to thank Simone Mieli, a biomedical webmaster, for the development of the www.D-MELD.com web-site and Mary V.C. Pragnell, BA, a professional medical writer for the assistance in revising the manuscript.

DISCLOSURE

All the authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation.

Figure 1. Enrolment and outcomes through month 60.

[At_the_bottom_of_Figure_1_(Enrolment_and_outcomes)]

*Patients with acute liver failure (ALF) were included. MELD exception points for patients with hepatocellular carcinoma (HCC) were not considered. Patients with MELD scores >40 (N=62, 1.2%) were reclassified as MELD 40.

~Exclusions were performed to avoid confusion with categorical variables characterized by a low number of cases. Although the match was not considered in cases of second transplants (N=270, 4.5%) and of third transplants (N=2, 0.04%), analysis was made of the follow-up of all patients (patient survival), including follow-up after re-transplant.

§Main indications for transplantation were reclassified according to Roberts.(18) Since in Italy there are fewer patients with primary sclerosing cholangitis and patients with primary biliary cirrhosis than in Northern Europe or in the United States, both categories (N=191, 3.6%) are included in the 'OTHER' group. Since the prevalence of concomitant etiologies was >20%, HCC, HCV, HBV status and/or alcohol abuse were treated in subsequent analyses as dichotomic variables.

\$Causes of failure/death were reclassified according to Adam.(19)

Figure 2. Performance of (A) donor age, (B) MELD, (C) D-MELD in the prediction of patient survival. All 3 curves are significant ($p < 0.0001$). The D-MELD curve is steeper.

Figure 3. Stratification of D-MELD deciles (A-C) and of D-MELD classes (B-D) in terms of patient and graft survivals.

Figure 4. Prevalences of D-MELD class A and D-MELD class C in HCC and non-HCC patients according to the transplant volume of the Center ($p < 0.001$). Variability of D-MELD reflects different policies concerning donor age limit and severity of recipient liver disease, in relation to different match modalities.

Figure 5. D-MELD cutoff identifying a population characterized by 5-year patient survival $< 50\%$ (5yrPS $< 50\%$) among HCV positive patients (including those with HCC). The cutoff (unsustainable match cutoff) was identified at D-MELD value 1750 in the training set (5-year patient survival = 44.2%, 95% CI 0.32-0.50), and validated in the validation set (5-year patient survival = 43.7%, 95% CI 0.28-0.49, data not shown). Being aware of potential implications, we built the model keeping the upper limit of the confidence interval below 50% at 5 years in both sets. (PLEASE LEAVE THE ITALIC TYPING)

Figure S1. Histograms of donor age, MELD, and D-MELD according to the 4 study biennia. For each box the median values and the prevalences according to their upper quartile and to their upper decile are reported.

Figure S2. Overall patient survival for recipients (A) by donor age ≥ 68 (upper quartile), (B) by donor age ≥ 75 (upper decile), (C) by MELD ≥ 21 (upper quartile), and (D) by MELD ≥ 28 (upper decile). Subanalyses of patient survival for recipients (a) by donor age ≥ 68 (upper quartile), (b) by donor age ≥ 75 (upper decile), (c) by MELD ≥ 21 (upper quartile), and (d) by MELD ≥ 28 (upper decile) according to the extremely high D-MELD class (C vs A+B).

References


1. Maluf DG, Edwards EB, Kauffman HM. Utilization of extended donor criteria liver allograft: is the elevated risk of failure independent of the model for end-stage liver disease score of the recipient? *Transplantation* 2006; 82: 1653-7.
2. Avolio AW, Nardo B, Agnes S, et al. The mismatch choice in liver transplantation: a suggestion for the selection of the recipient in relation to the characteristics of the donor. *Transplant Proc* 2005; 37: 2584-6.
3. Ioannou GN. Development and validation of a model predicting graft survival after liver transplantation. *Liver Transpl* 2006; 12: 1594-606.
4. Salizzoni M, Franchello A, Zamboni F, et al. Marginal grafts: finding the correct treatment for fatty livers. *Transpl Int* 2003; 16: 486-93.
5. Avolio AW, Agnes S, Nure E, et al. The non-standard liver, a hidden resource that cannot be overlooked: implications for the identification of the best recipient. *Transplant Proc* 2006; 38: 1055-8.
6. Burroughs A, Sabin CA, Rolls SK, et al. 3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. *Lancet* 2006; 367: 225-32.


7. Halldorson JB, Bakthavatsalam R, Fix O, Reyes JD, Perkins JD. D-MELD, a simple predictor of post liver transplant mortality for optimization of donor/recipient matching. *Am J Transplant* 2009; 9: 318-26.
8. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. *Hepatology* 2001; 33: 464-70.
9. Ravaioli M, Grazi GL, Cescon M, et al. Liver transplantations with donors aged 60 years and above: the low liver damage strategy. *Transpl Int* 2009; 22: 423-33.
10. Feng S, Goodrich NP, Bragg-Gresham JL, et al. Characteristics associated with liver graft failure: the concept of a donor risk index. *Am J Transplant* 2006; 6: 783-90.
11. Mutimer DJ, Gunson B, Chen J, et al. Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C virus. *Transplantation* 2006; 81: 7-14.
12. Bonney GK, Aldersley MA, Asthana S, et al. Donor risk index and MELD interactions in predicting long-term graft survival: a single-center experience. *Transplantation* 2009; 87: 1858-63.
13. Maluf DG, Edwards EB, Stravitz RT, Kauffman HM. Impact of the donor risk index on the outcome of hepatitis C virus-positive liver transplant recipients. *Liver Transpl* 2009; 15: 592-9.
14. Schaubel DE, Sima CS, Goodrich NP, Feng S et al. The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. *Am J Transplant* 2008; 8: 419-425.
15. Avolio AW, Gruttadauria S, Grieco A, et al. Comment to: Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor recipient matching. *Dig Liver Dis* 2011; 44: xxx-xxx (in press)
16. Angelico M, Cillo U, Fagioli S et al. Liver Match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching. *Dig Liver Dis* 2011; 43:155-64
17. Neuberger J, James O. Guidelines for selection of patients for liver transplantation in the era of donor-organ shortage. *Lancet* 1999; 354: 1636-9.
18. Roberts MS, Angus DC, Bryce CL, Valenta Z, Weissfeld L. Survival after liver transplantation in the United States: a disease-specific analysis of the UNOS database. *Liver Transpl* 2004; 10: 886-97.
19. Adam R, Cailliez V, Majno P, et al. Normalised intrinsic mortality risk in liver transplantation: European Liver Transplant Registry study. *Lancet* 2000; 356: 621-7.
20. Thuluvath PJ, Yoo HY, Thomponson RE. A model to predict survival at one month, one year, and five years after liver transplantation based on pretransplant clinical characteristics. *Liver Transpl* 2003; 9: 527-32.
21. Jacob M, Lewsey JD, Sharpin C, Gimson A, Rela M, von der Meulen JH. Systematic review and validation of prognostic models in liver transplantation. *Liver Transpl* 2005; 11: 814-25.
22. Kalil AC, Mattei J, Florescu DF et al. Recommendations for the assessment and reporting of

- multivariable logistic regression in transplantation literature. *Am J Transplant* 2010; 10: 1695-1703.
23. Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. *Lancet* 2010; 375: 895-905.
 24. Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S. A comparison of goodness-of-fit tests for the logistic regression model. *Sta Med* 1997; 16: 965-80.
 25. Avolio AW, Agnes S, Gasbarrini A, et al. Allocation of nonstandard livers to transplant candidates with high MELD scores: Should this practice be continued? *Transplant Proc* 2006; 38: 3567-71.
 26. Englesbe MJ, Schaubel DE, Cai S, Guidinger MK, Merion RM. Portal vein thrombosis and liver transplant survival benefit. *Liver Transpl* 2010; 16: 999-1005.
 27. Kim WR, Poterucha JJ, Kremers WK, Ishitani MB, Dickson ER. Outcome of liver transplantation for hepatitis B in the United States. *Liver Transpl* 2004; 10: 968-74.
 28. Valadao RM, Terrault NA. Older donors: mounting risks for the hepatitis C-infected liver transplant recipient? *Liver Transpl* 2009; 15: 677-81.
 29. Brooks BK, Levy MF, Jennings LW, et al. Influence of donor and recipient gender on the outcome of liver transplantation. *Transplant Proc* 1997; 29: 475-6.
 30. Watt KD, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. *Am J Transplant* 2010; 10: 1420-7.
 31. Dickson RC, Everhart JE, Lake JR, et al. Transmission of hepatitis B by transplantation of liver from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Disease Liver Transplantation Database. *Gastroenterology* 1997; 113: 1168-74.
 32. Mateo R, Cho Y, Singh G, et al. Risk factors for graft survival after liver transplantation from donation after cardiac death donors: an analysis of OPTN/UNOS data. *Am J Transplant* 2006; 6: 791-6.
 33. Mathur AK, Heimbach J, Steffick DE, Sonnenday CJ, Goodrich NP, Merion RM. Donation after cardiac death liver transplantation: predictors of outcome. *Am J Transplant* 2010; 10: 2512-
 34. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *New Engl J Med* 1996; 334: 693-99.
 35. Neuberger J, Gimson A, Akyol M, et al. Selection of patients for liver transplantation and allocation of donated livers in UK. *Gut* 2008; 57: 252-7.
 36. Brown RS Jr, Lake JR. The survival impact of liver transplantation in the MELD era, and the future for organ allocation and distribution. *Am J Transplant* 2005; 5: 203-4.
 37. Bruix J, Llovet JM: Prognostic prediction and treatment strategy in hepatocellular carcinoma. *Hepatology* 2002; 35: 519-524.
 38. Desai NM, Mange KC, Crawford MD, et al. Predicting outcome after liver transplantation: utility of the model for end-stage liver disease and a newly derived discrimination function. *Transplantation*, 2004; 77: 99-106.

39. Pacheco-Moreira LF, Balbi E, Enne M, et al. Liver transplantation for acute liver failure: trying to define when transplantation is futile. *Transpl Proc* 2007; 39: 3178-81.
40. Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA. The survival benefit of liver transplantation. *Am J Transplant* 2005; 5: 307-13.
41. Schaubel DE, Guidinger MK, Biggins SW et al. Survival benefit-based deceased-donor liver allocation. *Am J Transplant* 2009; 9: 970-981.
42. Ravaioli M, Grazi GL, Dazzi A, et al. Survival benefit after liver transplantation: a single european Center experience. *Transplantation* 2009; 88: 826-34.
43. Cillo U, Vitale A, Volk ML, et al. The survival benefit of liver transplantation in hepatocellular carcinoma patients. *Dig Liver Dis* 2010; 42: 642-9.
44. Edwards EB, Roberts JP, McBride MA, Schulak JA, Hunsicker LG. The effect of the volume of procedures at transplantation Centers on mortality after liver transplantation. *New Engl J Med* 1999; 341: 2049-53.
45. Axelrod DA, Guidinger MK, McCullough KP, et al. Association of center volume with outcome after liver and kidney transplantation. *Am J Transpl* 2004; 4: 920-7.

Figure 1





Whole Model Test

<u>X-Model</u>	<u>-LogKikelihood</u>	<u>DF</u>	<u>ChiSq</u>	<u>Prob>ChiSq</u>
Difference Donor Age	26.9855	1	53.9710	<.0001
Difference MELD	26.3366	1	52.6732	<.0001
Difference D-MELD	46.8161	1	93.6323	<.0001

Figure 2





Figure 3

HCC

D-MELD class A

D-MELD class C



Non HCC




Figure 4

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49




Figure 5

Table 1. Descriptive statistics according to the D-MELD class in the training set.

	D-MELD Class A (<338) N=332	D-MELD Class B (338-1628) N=2621	D-MELD Class C (>1628) N=328	p-value
D-MELD (N=3281; 100.0%)	250.0±60.3	834.3±325.7	2089.7±397.3	<0.001*
MELD (N=3281; 100.0%)	11.5±4.3	16.1±6.2	30.5±5.8	<0.001*
<i>MELD in HCC+</i> (N=1380; 42.1%)	10.1±5.2	13.7±5.5	28.1±5.2	<0.001*
<i>MELD in HCV+</i> (N=1570; 47.9%)	11.8±4.0	15.6±5.7	29.5±5.4	<0.001*
<i>MELD in HCV+ HCC+</i> (N=789; 24.1%)	10.5±3.2	13.9±5.3	27.5±4.8	<0.001*
<i>MELD in HCV+ HCC-</i> (N=781; 23.8%)	13.7±4.3	17.5±5.9	30.6±5.4	<0.001*
Recipient age (N=3260; 99.3%)	50.3±11.2	53.5±9.1	49.7±10.5	<0.001*
Recipient gender (N=3203; 97.6%)				
- Male	239 (74.0)	1976 (77.2)	224 (69.6)	<0.001
HCV status (N=3281; 100.0%)				
- Positive	138 (41.6)	1287 (49.1)	146 (44.5)	0.016
HBV status (N=3281; 100.0%)				
- Positive	85 (25.6)	670 (25.5)	76 (23.2)	0.643
Alcohol status (N=3281; 100.0%)				
- Positive	48 (14.5)	494 (18.8)	45 (13.7)	0.017
Acute liver failure status (N=3281; 100.0%)				
- Positive	3 (0.9)	41 (1.6)	37 (13.3)	<0.001
HCC (N=3281; 100.0%)				
- Positive	156 (47.0)	1151 (43.9)	76 (23.2)	<0.001
Pre-Tx abdominal surgery (N=2609; 79.5%)				
- Yes	58 (21.6)	365 (18.8)	40 (16.5)	0.331
Dialysis (N=2546; 77.6%)				
- Yes	0 (0.0)	8 (0.4)	9 (3.6)	<0.001
Pre-Tx portal thrombosis (N= 2814; 85.7%)				
- Yes	14 (5.0)	172 (7.7)	29 (10.1)	<0.001
Listing months (N=3038; 92.5%)	8.2±8.6	7.7±8.2	5.9±8.5	<0.001*
Re-transplant (N=3281; 100.0%)				
- Yes	10 (3.0)	127 (4.8)	21 (6.4)	0.125
Donor age (N=3281; 100.0%)	24.3±10.1	54.6±16.3	69.3±10.0	<0.001*
Donor gender (N=3197; 97.4%)				
- Male	230 (71.2)	1416 (55.5)	163 (50.8)	<0.001
Donor HBcAb (N=3070; 93.5%)				
- Yes	34 (11.4)	410 (16.7)	59 (18.7)	0.003
Donor-Recipient gender match (N=3190; 97.2%)				
- Female→Female	38 (11.8)	355 (13.9)	57 (17.8)	
- Female→Male	55 (17.0)	783 (30.7)	94 (31.5)	
- Male→Female	46 (14.2)	224 (8.8)	41 (12.8)	
- Male→Male	184 (57.0)	1191 (46.6)	122 (37.9)	<0.001
Donor-Recipient gender concordance (N=3197; 97.4%)				
- Yes	222 (68.7)	1547 (60.6)	179 (55.8)	0.003
Cold Ischemia Time^o (N=2705; 82.4%)	8.2±2.1	9.1±3.3	6.9±2.7	0.043*
Biennium (N=3281; 100.0%)				
- 2002-2003	66 (19.9)	343 (13.1)	32 (9.8)	
- 2004-2005	79 (23.8)	713 (27.2)	87 (26.5)	
- 2006-2007	96 (28.9)	781 (29.8)	114 (34.7)	
- 2008-2009	91 (27.4)	786 (29.9)	95 (29.0)	0.005
Volume of the centre (N=3281; 100.0%)				
- Low	144 (43.4)	882 (33.7)	60 (18.3)	
- Medium	99 (29.8)	839 (32.0)	113 (34.5)	
- High	89 (26.8)	900 (34.3)	155 (47.3)	<0.001

Means and Standard Deviations are reported for continuous variables; absolute and relative frequencies are reported for categorical ones.

*Kruskal-Wallis test; all the other p-values were obtained by Chi² test. ^o Hour

Table 2. Predictive factors of mortality and graft failure at 90 days, 1 and 3 years by Logistic Regression in the training set.

	mortality at 90 days			mortality at 1 year			mortality at 3 years			graft failure at 90 days			graft failure at 1 year			graft failure at 3 years		
	OR	(95% CI)	<i>p</i>	OR	(95% CI)	<i>p</i>	OR	(95% CI)	<i>p</i>	OR	(95% CI)	<i>p</i>	OR	(95% CI)	<i>p</i>	OR	(95% CI)	<i>p</i>
D-MELD[§]																		
Class A vs B	0.46	(0.24-0.86)	0.015	0.43	(0.26-0.72)	0.001	0.40	(0.24-0.66)	<0.001	0.41	(0.24-0.72)	0.002	0.41	(0.26-0.66)	<0.001	0.42	(0.27-0.67)	<0.001
Class C vs B	2.65	(1.81-3.89)	<0.001	2.32	(1.68-3.21)	<0.001	2.03	(1.44-2.85)	<0.001	2.16	(1.54-3.03)	<0.001	2.05	(1.52-2.77)	<0.001	1.92	(1.39-2.67)	<0.001
Recipient age	1.013	(0.997-1.029)	0.099	1.018	(1.005-1.031)	0.008	1.015	(1.002-1.028)	0.024*	1.007	(0.993-1.020)	0.32	1.01	(0.999-1.022)	0.079	1.008	(0.996-1.020)	0.181
HCV status																		
Positive vs negative	0.98	(0.72-1.33)	0.887	1.16	(0.90-1.48)	0.249	1.42	(1.11-1.81)	0.006	0.99	(0.77-1.29)	0.966	1.13	(0.91-1.41)	0.275	1.42	(1.12-1.79)	0.004*
HBV status																		
Positive vs negative	0.89	(0.62-1.26)	0.503	0.72	(0.53-0.96)	0.027	0.69	(0.51-0.93)	0.015*	0.86	(0.64-1.16)	0.328°	0.72	(0.55-0.94)	0.014	0.72	(0.54-0.95)	0.019
Pre-tx portal thrombosis																		
Yes vs no	1.9	(1.21-2.96)	0.005*	1.43	(0.97-2.11)	0.07	1.46	(0.97-2.20)	0.071	1.85	(1.26-2.71)	0.002	1.51	(1.06-2.15)	0.021	1.47	(0.99-2.17)	0.056
Re-transplant																		
Yes vs no	2.61	(1.62-4.22)	<0.001	2.73	(1.83-4.08)	<0.001	1.82	(1.16-2.87)	0.010*	-	-	-	-	-	-	-	-	-
Biennium																		
'02-'03 vs '08-'09	1.26	(0.83-1.91)	0.287	0.99	(0.69-1.41)	0.94	0.83	(0.61-1.13)	0.24	1.21	(0.84-1.74)	0.304	0.99	(0.72-1.38)	0.959	0.92	(0.69-1.23)	0.578
'04-'05 vs '08-'09	0.85	(0.58-1.25)	0.407	0.86	(0.63-1.16)	0.319	0.75	(0.58-0.97)	0.027*	0.82	(0.59-1.13)	0.228	0.81	(0.61-1.07)	0.135	0.72	(0.57-0.92)	0.009*
'06-'07 vs '08-'09	0.83	(0.57-1.19)	0.308	0.85	(0.63-1.14)	0.282	-	-	-	0.72	(0.53-0.99)	0.045*	0.78	(0.59-1.02)	0.068	-	-	-
Volume of the centre																		
Low vs medium	2.21	(1.56-3.12)	<0.001	1.91	(1.43-2.54)	<0.001*	1.48	(1.11-1.99)	0.008	1.56	(1.15-2.12)	0.004*	1.57	(1.24-2.04)	0.001*	1.27	(0.96-1.68)	0.094
High vs medium	0.64	(0.43-0.94)	0.022*	0.83	(0.62-1.12)	0.219°	0.85	(0.64-1.13)	0.26	0.81	(0.59-1.10)	0.175°	0.95	(0.73-1.23)	0.705	0.91	(0.70-1.19)	0.503
Hosmer Lemeshow (training set)			0.259			0.731			0.702			0.317			0.607			0.527
Hosmer Lemeshow (validation set)			0.444			0.31			0.643			0.9			0.132			0.862
°significant in the validation se																		
*NOT significant in the validation set																		
C-statistic (training set)			0.690			0.664			0.667			0.640			0.624			0.633
C-statistic (validation set)			0.733			0.698			0.672			0.687			0.668			0.662

[§]D-MELD was analysed also as a continuous variable. To comply with the 4 digit integers, D-MELD values were divided by 100 in order to achieve 2 digit decimals of Odd Ratio (OR). OR, 95% CI and significances at 90 days, 1 year, 3 years were 1.08 (1.05-1.11) p<0.001; 1.08 (1.05-1.09) p<0.001; 1.07 (1.05-1.09) p<0.001; for mortality and 1.07 (1.05-1.09) p<0.001; 1.07 (1.05-1.09) p<0.001; 1.06 (1.05-1.08) p<0.001; for graft failure. In other words, at 3 years for each 100 point D-MELD increment the relative risk increases of 1.07 for mortality and 1.06 for graft failure.

Table 3. Predictive factors at the Cox regression in the training set.

	overall mortality (1 to 90 months)			overall graft failure (1 to 90 months)		
	HR	(95% CI)	<i>p-value</i>	HR	(95% CI)	<i>p-value</i>
D-MELD[§]						
Class A vs class B	0.42	(0.29-0.60)	<0.001	0.41	(0.29-0.58)	<0.001
Class C vs class B	1.97	(1.59-2.43)	<0.001	1.86	(1.53-2.27)	<0.001
Recipient age	1.015	(1.006-1.024)	0.001	1.008	(1.000-1.016)	0.047*
HCV status						
Positive vs negative	1.43	(1.21-1.70)	<0.001	1.40	(1.20-1.64)	<0.001**
HBV status						
Positive vs negative	0.72	(0.58-0.89)	0.002	0.75	(0.62-0.91)	0.004
Re-transplant						
Yes vs no	2.21	(1.70-2.87)	<0.001	-	-	-
Biennium						
2002-2003 vs 2008-2009	1.28	(0.99-1.65)	0.096	1.14	(1.07-1.71)	0.010*
2004-2005 vs 2008-2009	1.06	(0.84-1.33)	0.627	1.03	(0.84-1.27)	0.784
2006-2007 vs 2008-2009	1.28	(0.99-1.65)	0.056	1.09	(0.89-1.33)	0.416
Volume of the centre						
Low vs medium	1.35	(1.11-1.65)	0.003*	1.19	(0.99-1.45)	0.059
High vs medium	0.92	(0.76-1.12)	0.391	0.98	(0.82-1.17)	0.779
C-statistics						
Training set			0.641			0.701
Validation set			0.643			0.721

* not significant in the validation set

** 0.051 in the validation set

[§]D-MELD was analysed also as a continuous variable. To comply with the 4 digit integers, D-MELD values were divided by 100 in order to achieve 2 digit decimals of Hazard Ratio (HR). HR (95% CI) and significances were 1.06 (1.04-1.07) p<0.001 for mortality and 1.06 (1.05-1.07) p<0.001 for graft failure. In other words, for each 100 point D-MELD increment the relative risk increases of 1.06 for mortality and 1.06 for graft failure.




Figure S1

DONOR AGE

MELD

D-MELD




Figure S2

Table S1. Kaplan Meier analysis p-value in the training set.**Patient survival**

D-MELD decile		1	2	3	4	5	6	7	8	9
		<i>p</i>	<i>p</i>	<i>p</i>	<i>p</i>	<i>p</i>	<i>p</i>	<i>p</i>	<i>p</i>	<i>p</i>
Mantel Cox	1									
	2	.022								
	3	.000	.127							
	4	.013	.872	.169						
	5	.000	.014	.363	.023					
	6	.000	.002	.127	.004	.530				
	7	.000	.015	.350	.021	.980	.525			
	8	.000	.007	.245	.010	.769	.721	.798		
	9	.000	.005	.199	.007	.699	.847	.698	.889	
	10	.000	.000	.000	.000	.002	.013	.001	.004	.005
Breslow	1									
	2	.022								
	3	.000	.109							
	4	.019	.961	.118						
	5	.000	.031	.623	.037					
	6	.000	.003	.174	.004	.340				
	7	.000	.029	.577	.033	.927	.387			
	8	.000	.009	.332	.010	.574	.680	.652		
	9	.000	.008	.314	.009	.568	.718	.648	.976	
	10	.000	.000	.000	.000	.000	.010	.000	.002	.002

Graft survival

D-MELD decile		1	2	3	4	5	6	7	8	9
		<i>p</i>	<i>p</i>	<i>p</i>	<i>p</i>	<i>p</i>	<i>p</i>	<i>p</i>	<i>p</i>	<i>p</i>
Mantel Cox	1									
	2	.019								
	3	.000	.068							
	4	.005	.663	.158						
	5	.000	.002	.223	.009					
	6	.000	.000	.053	.001	.476				
	7	.000	.010	.422	.028	.623	.237			
	8	.000	.003	.250	.010	.958	.430	.707		
	9	.000	.001	.146	.004	.818	.664	.481	.747	
	10	.000	.000	.000	.000	.003	.022	.000	.002	.005
Breslow	1									
	2	.027								
	3	.000	.065							
	4	.012	.774	.114						
	5	.000	.004	.314	.010					
	6	.000	.000	.068	.001	.388				
	7	.000	.023	.669	.044	.539	.141			
	8	.000	.004	.317	.009	.987	.390	.541		
	9	.000	.002	.208	.004	.788	.567	.383	.792	
	10	.000	.000	.000	.000	.002	.027	.000	.002	.004

	% Patient survival							% Graft survival						
	12	24	36	48	60	72	mo P	12	24	36	48	60	72	mo P
D-MELD														
- Class A (66-336)	95	93	92	90	89	88		93	91	89	88	88	87	
- Class B (338-1628)	88	84	80	78	76	74		85	80	77	75	73	71	
- Class C (1632-3240)	77	72	69	65	63	61	<0.001	73	68	65	62	58	56	<0.001
Donor age														
- 1 decile (12-24)	89	88	87	86	85	84		89	87	86	85	84	84	
- 2 decile (24-35)	93	91	89	86	86	86		91	89	86	84	84	84	
- 3 decile (35-44)	87	83	82	80	79	79		84	80	78	76	76	76	
- 4 decile (44-51)	87	83	79	77	75	71		84	80	76	75	73	69	
- 5 decile (51-56)	87	86	82	81	78	77		84	82	77	76	74	74	
- 6 decile (56-60)	87	82	79	75	73	69		83	79	75	72	69	66	
- 7 decile (60-66)	87	81	78	77	74	70		83	79	74	71	69	66	
- 8 decile (66-70)	85	81	78	75	73	72		83	79	77	73	71	70	
- 9 decile (70-76)	85	79	73	69	63	62		82	75	70	66	61	60	
- 10 decile (76-97)	87	79	77	73	70	63	<0.001	80	73	71	68	65	58	<0.001
MELD														
- 1 decile (6-8)	94	90	86	85	83	83		91	86	82	82	80	80	
- 2 decile (9-10)	90	88	85	81	77	75		88	85	81	78	74	72	
- 3 decile (11-12)	93	86	82	81	80	79		90	83	79	78	77	76	
- 4 decile (13-13)	87	82	78	76	75	73		81	77	74	72	70	69	
- 5 decile (14-15)	87	83	80	78	78	76		85	80	78	76	76	73	
- 6 decile (16-17)	90	86	82	78	73	72		87	81	78	73	69	68	
- 7 decile (18-19)	88	84	81	78	76	70		86	81	78	77	74	67	
- 8 decile (20-22)	82	80	80	78	74	72		81	79	79	77	73	71	
- 9 decile (23-28)	84	82	78	74	72	72		80	77	73	70	68	68	
- 10 decile (29-41)	77	72	70	70	70	69	<0.001	74	70	67	67	67	65	<0.001
Recipient age														
- ≥ 60 years	85	80	77	74	72	69		83	78	75	72	70	68	
- < 60 years	88	84	81	80	77	75	0.002	85	81	77	76	74	72	0.048
Recipient gender														
- Male	88	84	80	78	75	73		85	81	78	74	72	70	
- Female	85	81	79	77	76	74	0.596	82	77	75	74	73	72	0.624
HCV status														
- Positive	86	80	76	73	69	66		82	77	73	70	66	64	
- Negative	87	86	84	83	82	81	<0.001	86	83	81	80	79	78	<0.001
HBV status														
- Positive	91	88	86	85	83	83		88	85	83	82	81	80	
- Negative	87	82	78	75	73	70	<0.001	83	78	75	72	70	68	<0.001
Alcohol status														
- Positive	87	85	81	79	77	75		84	81	77	75	74	72	
- Negative	87	83	80	78	76	74	0.672	84	80	77	75	73	71	0.895
Acute liver failure status														
- Positive	75	73	73	71	71	71		75	73	71	69	69	69	
- Negative	87	84	80	78	76	74	0.044*	85	80	77	75	73	71	0.161
HCC status														
- Positive	89	84	80	78	75	73		87	82	77	75	72	71	
- Negative	86	83	80	78	75	73	0.703	82	80	77	75	73	71	0.271
Pre-Tx abdominal surgery														
- Yes	86	82	80	78	76	76		82	78	76	73	72	72	
- No	87	83	80	77	75	72	0.796	84	80	77	74	73	70	0.621
Pre-Tx portal thrombosis														
- Yes	82	80	77	74	74	72		78	75	72	69	69	67	
- No	87	83	80	78	75	73	0.306	84	80	76	74	72	70	0.103
Dialysis														
- Yes	65	65	58	58	58	58		71	64	57	57	57	57	
- No	88	84	81	79	76	74	0.007	85	81	78	75	73	71	0.042*
Listing days														
- ≥90	86	83	80	77	76	73		82	77	74	73	70	70	
- <90	88	84	81	79	77	74	0.286	85	80	77	75	73	71	0.352
Re-transplant														
- Yes	74	69	65	59	55	50								
- No	88	84	81	79	77	75	<0.001							
Donor age														
- ≥ 60 years	85	80	76	73	70	67		82	76	72	69	66	64	
- < 60 years	88	86	83	81	80	78	<0.001	86	83	80	78	77	76	<0.001
Donor gender														
- Male	87	83	80	76	75	74		84	80	76	74	72	71	
- Female	87	83	80	78	75	74	0.981	84	80	77	75	73	70	0.894
Donor HBcAb														
- Positive	87	83	80	78	76	73		84	80	76	76	70	69	
- Negative	88	83	80	77	75	74	0.971	84	80	77	75	73	71	0.524
Donor-recipient gender match														
- Female->Male	88	84	80	78	76	73		85	81	77	75	73	70	
- Female->Female	85	81	80	78	76	74		82	77	76	74	73	71	
- Male->Female	85	81	79	76	76	75		82	78	76	74	73	72	
- Male->Male	87	84	80	77	75	73	0.972	84	81	77	74	72	70	0.928
Donor-recipient gender concordance														
- Yes	87	83	80	77	75	73		84	80	76	74	72	70	
- No	87	83	80	78	76	74	0.835	85	80	77	75	73	71	0.608
Cold ischemia time														
- ≥ 8 hours	86	82	79	76	75	73		83	80	76	75	74	73	
- < 8 hours	87	84	81	78	76	74	0.641	84	81	78	76	75	74	0.721
Biennium														
- 2002-2003	86	83	80	78	74	71		82	78	75	73	70	68	
- 2004-2005	87	82	80	78	77	75		84	80	78	75	74	73	
- 2006-2007	87	83	80	77	76			85	81	76	74	73		
- 2008-2009	88	85					0.274	85	82					0.107
Centre volume														
- Low	84	81	78	76	74	70		82	79	76	74	73	69	
- Medium	88	84	80	79	76	76		85	80	77	75	73	72	
- High	89	85	82	79	77	75	0.016*	85	81	78	75	73	72	0.394

*Not significant in the validation set.

Table S3. Kaplan Meier curves in the validation set.

	% Patient survival							% Graft survival						
	12	24	36	48	60	72	mo P	12	24	36	48	60	72	mo P
D-MELD														
- Class A (66-336)	96	92	90	88	88	87		94	90	88	87	87	86	
- Class B (338-1628)	88	83	80	77	75	73		84	79	76	73	72	70	
- Class C (1632-3240)	71	68	67	63	61	61	<0.001	64	62	61	58	58	58	<0.001
Donor age														
- 1 decile (12-24)	90	87	84	82	82	82		88	84	81	80	80	80	
- 2 decile (24-35)	88	84	83	81	79	74		85	82	81	79	77	74	
- 3 decile (35-44)	90	87	85	82	81	81		89	85	82	80	79	79	
- 4 decile (44-51)	89	85	82	80	79	79		86	83	80	78	75	75	
- 5 decile (51-56)	89	84	80	79	78	75		86	80	77	76	75	71	
- 6 decile (56-60)	88	84	77	72	71	71		88	83	75	73	70	70	
- 7 decile (60-66)	88	83	80	80	78	75		85	79	77	76	75	72	
- 8 decile (66-70)	83	76	74	72	72	70		80	72	72	68	68	66	
- 9 decile (70-76)	77	72	69	64	57	54		72	66	62	58	55	52	
- 10 decile (76-97)	87	85	80	69	68	68	<0.001	79	78	73	64	61	61	<0.001
MELD														
- 1 decile (6-8)	92	88	83	78	77	73		90	84	80	75	73	70	
- 2 decile (9-10)	93	88	85	81	81	79		89	85	81	78	76	74	
- 3 decile (11-12)	93	91	88	84	84	84		90	87	84	80	80	80	
- 4 decile (13-13)	87	81	79	77	73	70		83	78	75	75	75	69	
- 5 decile (14-15)	91	88	82	79	77	77		89	86	80	77	76	76	
- 6 decile (16-17)	89	82	79	79	77	72		85	78	75	74	73	68	
- 7 decile (18-19)	85	80	77	74	71	67		81	76	73	70	67	64	
- 8 decile (20-22)	87	82	81	76	73	73		83	76	75	71	67	65	
- 9 decile (23-28)	81	77	75	75	75	73		78	74	72	72	72	70	
- 10 decile (29-41)	69	67	63	62	60	60	<0.001	65	63	60	60	60	60	<0.001
Recipient age														
- ≥ 60 years	83	77	74	72	69	65		80	75	72	70	68	64	
- < 60 years	89	84	81	78	77	75	<0.001	85	80	77	75	73	72	0.017
Recipient gender														
- Male	87	83	80	77	75	73		84	80	77	74	72	70	
- Female	85	80	77	75	74	72	0.102	81	76	73	71	71	69	0.289
HCV status														
- Positive	85	79	75	71	70	67		82	76	72	68	66	64	
- Negative	89	86	84	82	80	78	<0.001	85	82	80	78	77	76	<0.001
HBV status														
- Positive	92	88	86	84	83	82		90	87	85	83	82	81	
- Negative	85	80	77	74	72	70	<0.001	82	76	73	70	69	66	<0.001
Alcohol status														
- Positive	88	84	82	80	77	77		83	79	77	75	74	73	
- Negative	87	82	79	76	74	72	0.198	84	79	76	73	72	70	0.626
Acute liver failure status														
- Positive	75	75	75	71	71	71		69	69	69	65	65	65	
- Negative	87	83	79	77	75	73	0.264	84	79	76	74	72	70	0.124
HCC status														
- Positive	89	84	80	76	73	71		88	82	78	74	71	68	
- Negative	85	81	79	77	76	74	0.859	81	77	75	73	72	71	0.202
Pre-Tx abdominal surgery														
- Yes	86	83	81	76	74	72		84	80	78	75	75	70	
- No	86	82	78	75	74	73	0.727	83	78	75	72	71	70	0.424
Pre-Tx portal thrombosis														
- Yes	82	74	70	70	70	70		78	70	66	66	66	66	
- No	87	83	79	76	74	73	0.133	83	79	76	73	71	70	0.129
Dialysis														
- Yes	58	58	58	58	58	58		58	58	58	58	58	58	
- No	88	84	80	77	75	74	0.018	85	80	76	73	72	71	0.061
Listing days														
- ≥90	88	84	81	78	76	74		85	80	78	75	73	72	
- <90	86	81	78	75	74	72	0.163	82	77	73	72	70	68	0.091
Re-transplant														
- Yes	67	61	61	55	53	50								
- No	88	84	80	80	76	75	<0.001							
Donor age														
- ≥ 60 years	84	79	76	72	75	77		79	74	71	67	66	63	
- < 60 years	89	85	82	80	79	77	<0.001	87	83	80	78	77	75	<0.001
Donor gender														
- Male	87	82	80	77	74	72		84	79	76	74	72	69	
- Female	87	83	80	77	76	75	0.501	83	79	75	73	72	71	0.799
Donor HBcAb														
- Positive	83	79	75	72	71	71		79	75	71	69	68	66	
- Negative	88	83	80	77	75	73	0.106	84	79	76	74	72	71	0.119
Donor-recipient gender match														
- Female->Male	86	83	80	76	76	75		84	78	75	73	72	71	
- Female->Female	86	83	80	77	75	74		83	78	75	73	72	71	
- Male->Female	81	77	75	73	72	69		77	73	71	69	69	67	
- Male->Male	88	84	80	77	75	72	0.531	86	81	78	75	72	70	0.435
Donor-recipient gender concordance														
- Yes	88	84	80	77	75	73		85	78	77	74	72	70	
- No	85	81	79	76	74	73	0.589	81	77	74	72	71	70	0.339
Cold ischemia time														
- ≥ 8 hours	85	83	80	78	75	73		83	80	77	76	74	72	
- < 8 hours	87	85	82	79	76	75	0.538	85	82	79	75	74	73	0.597
Biennium														
- 2002-2003	89	85	83	80	77	75		85	81	79	75	73	71	
- 2004-2005	86	82	79	77	75	74		83	79	76	74	73	71	
- 2006-2007	84	80	77	74	74		81	77	77	71	71			
- 2008-2009	89	83					0.296	86	80					0.353
Centre volume														
- Low	85	80	77	74	72	71		83	78	74	71	70	69	
- Medium	86	83	80	78	76	74		82	79	76	74	73	70	
- High	87	84	81	78	76	74	0.139	85	80	77	74	73	70	0.558

ScholarOne support: (434) 964 4100

p values were obtained by Mantel Cox tests.

Table S4. Expected and observed number of deaths and failures at 1 and 3 years stratified in deciles of estimated risk in the training set and in the validation set (Hosmer-Lemeshow test).

At 1 years	Exitus			Exitus			Failure		Failure	
	Training set			Validation set			Training set		Validation set	
	Decile	Observed	Expected	Observed	Expected	Observed	Expected	Observed	Expected	
	1	12	12.9	8	5.1	21	19.4	9	8.0	
	2	20	19.3	11	7.9	24	28.4	15	11.4	
	3	25	23.1	9	10.7	32	34.5	13	14.7	
	4	24	26.4	10	12.6	35	38.0	17	19.0	
	5	34	29.7	12	14.8	53	41.4	17	22.1	
	6	33	33.5	16	17.1	40	45.2	32	24.3	
	7	37	39.5	18	20.4	52	50.0	19	27.3	
	8	50	48.0	18	24.4	59	56.4	35	30.3	
	9	47	57.7	37	30.2	62	64.7	28	33.7	
	10	85	76.9	54	49.7	78	78.0	63	57.2	
Hosmer-Lemeshow test			0.731	0.310	0.607	0.132				

At 3 years	Exitus			Exitus			Failure		Failure	
	Training set			Validation set			Training set		Validation set	
	Decile	Observed	Expected	Observed	Expected	Observed	Expected	Observed	Expected	
	1	9	15.3	9	8.1	14	21.3	11	10.9	
	2	24	23.1	15	11.4	35	30.8	15	14.4	
	3	31	27.9	14	13.8	37	35.6	15	17.8	
	4	31	32.4	14	16.5	38	40.7	26	21.7	
	5	38	36.8	17	19.3	51	44.8	22	24.9	
	6	39	40.5	23	21.8	47	48.0	27	27.2	
	7	49	45.4	23	24.8	53	53.7	32	29.4	
	8	57	51.4	23	28.0	64	58.1	27	32.1	
	9	60	59.5	39	32.1	66	65.0	38	35.8	
	10	69	74.8	41	42.2	71	78.2	48	46.8	
Hosmer-Lemeshow test			0.259	0.643	0.527	0.862				